Heparin Dosing for Extensive Lower Limb DVT
For extensive lower limb deep vein thrombosis, use weight-based unfractionated heparin with an 80 U/kg IV bolus followed by 18 U/kg per hour continuous infusion, targeting an aPTT of 1.5-2.5 times control (corresponding to anti-Factor Xa levels of 0.3-0.7 IU/mL). However, low-molecular-weight heparin (LMWH) is preferred over unfractionated heparin for most patients with acute DVT.
Preferred Anticoagulation Strategy
LMWH is the preferred initial treatment over unfractionated heparin for extensive lower limb DVT 1. The specific dosing options include:
- Enoxaparin: 1 mg/kg subcutaneously every 12 hours, or 1.5 mg/kg once daily 1
- Dalteparin: 200 U/kg subcutaneously once daily 1
The guidelines favor LMWH over IV unfractionated heparin (grade 2C) and subcutaneous unfractionated heparin (grade 2B) 1.
When to Use Unfractionated Heparin
Unfractionated heparin remains appropriate in specific clinical scenarios:
IV Administration (Preferred Route)
- Initial bolus: 80 U/kg IV 1, 2
- Maintenance infusion: 18 U/kg per hour 1, 2
- Target aPTT: 1.5-2.5 times control, corresponding to anti-Factor Xa levels of 0.3-0.7 IU/mL 1, 2
Subcutaneous Administration (Alternative)
The subcutaneous regimen was shown to be as safe and effective as IV heparin in the FIDO trial 1.
Monitoring Requirements
For Unfractionated Heparin:
- Baseline: aPTT, INR, platelet count, CBC 2
- During IV infusion: Check aPTT approximately every 4 hours initially, then at appropriate intervals 2
- During subcutaneous therapy: Check aPTT 4-6 hours after injection 2
- Platelet monitoring: Every 2-3 days from day 4 to day 14 to screen for heparin-induced thrombocytopenia (HIT), which occurs in up to 5% of patients 1
For LMWH:
- Routine aPTT monitoring is not required 1
- Platelet monitoring is not routinely indicated due to lower HIT risk 1
- Exception: In renal insufficiency (CrCl <30 mL/min), use caution with LMWH or avoid entirely; may require anti-Factor Xa monitoring 1
Critical Considerations for Extensive DVT
Why "Extensive" Matters:
Extensive DVT (proximal extension beyond calf veins) carries higher risk of pulmonary embolism and requires full therapeutic anticoagulation, not prophylactic dosing 1.
Renal Function Impact:
- CrCl <30 mL/min: LMWH is contraindicated or requires dose adjustment with anti-Xa monitoring 1. Unfractionated heparin becomes the preferred option in severe renal impairment.
- Fondaparinux: Contraindicated if CrCl <30 mL/min 1
Duration of Initial Therapy:
- Continue parenteral anticoagulation for minimum 5 days AND until INR ≥2.0 for at least 24 hours if bridging to warfarin 1
- For cancer patients, consider LMWH monotherapy for the entire treatment course (at least 3-6 months) 3
Common Pitfalls to Avoid
Inadequate initial anticoagulation: Failure to achieve therapeutic aPTT (≥1.5 times control) within 24 hours is associated with 25% risk of recurrent VTE 1. Use weight-based dosing, not empiric dosing.
Wrong heparin vial selection: Fatal medication errors have occurred from confusing therapeutic heparin vials with catheter lock flush vials 2. Always verify concentration before administration.
Missing HIT: Monitor platelets every 2-3 days from day 4-14 when using unfractionated heparin 1. A 50% drop in platelet count suggests HIT.
Using LMWH in severe renal failure: LMWH accumulates when CrCl <30 mL/min, increasing bleeding risk 1.
Premature discontinuation: Continue therapeutic anticoagulation for at least 3 months for extensive DVT 4.
Alternative Agents
Fondaparinux is also preferred over unfractionated heparin (grade 2C) 1:
- <50 kg: 5 mg subcutaneously daily
- 50-100 kg: 7.5 mg subcutaneously daily
100 kg: 10 mg subcutaneously daily 1
Direct oral anticoagulants (rivaroxaban, apixaban) can be initiated without parenteral lead-in for most patients 4, though this is outside the scope of heparin dosing.